Vysis files for approval of breast cancer gene test:
This article was originally published in Clinica
Executive Summary
Genetic analysis firm Vysis has filed a premarket approval application with the FDA to market a test for the HER-2 breast cancer gene. In large quantities, HER-2 is associated with aggressive, difficult-to-treat cancer and a poor prognosis. Vysis test, called PathVysion, is a DNA probe kit which will be used with fluorescence in situ hybridisation, a technique in which DNA probes are labelled with a fluorescent marker which can be detected when the probe binds to the target gene. Vysis' test includes a second probe which is specific for chromosome 17, where the HER-2 gene resides. Vysis is based in Downers Grove, Illinois.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.